Trials / Completed
CompletedNCT04811365
(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
Study Evaluating the Prevalence of the KIT D816V Mutation in Peripheral Blood of Patients With Evidence of Systemic Mast Cell Activation (MCA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 379 (actual)
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Screening | After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms |
Timeline
- Start date
- 2021-06-29
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2021-03-23
- Last updated
- 2023-04-06
Locations
23 sites across 8 countries: United States, Belgium, France, Germany, Italy, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT04811365. Inclusion in this directory is not an endorsement.